Hancock Jaffe Announces Reverse Stock Split

Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1 for 25 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. Eastern time on November 30, 2020 and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on November 30, 2020 under the Company's existing trading symbol "HJLI". At such time, the Company's common stock will also commence trading under a new CUSIP number 41015N304.